Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2001

View Archived Issues

Gilead launches Viread this week in U.S.

Preliminary findings reported at AACR-NCI-EORTC from ongoing phase I studies of new GARFT inhibitor

Active Biotech commences phase II trials of MS treatment

MediChem receives SBIR grant for topoisomerase I inhibitors

Preclinical data support clinical development of XR-5944 and XR-11576

NN-622 development continues without Novartis

MedImmune licenses rights to cancer targets

Inex c-myc antisense oligonucleotide well tolerated in phase I study in combination with cisplatin

Medivir compound targeting multiresistant HIV enters phase IIa trial

Two vaccines for HPV prove effective in clinical trials

Zelmac receives Swiss approval for treatment of IBS

Positive interaction demonstrated between PI-88 and several cytotoxic agents in animal tumor model

Therion secures financing to advance lead cancer vaccine into phase III trials

Remitogen and Rituxan assessed in combination in cancer patients

AACR-NCI-EORTC news: little severe toxicity seen in dose-escalating trial of IL-2 mutein

Esperion offers brief update of Q3 developments

Orally active KDR tyrosine kinase inhibitor effective in spontaneously metastatic human tumor model

Corvas updates rNAPc2 development and reviews progress in cancer programs

Phase I study results for NV-06 presented by Australian investigators in Miami Beach

Chimeric bikunin molecule shown to suppress ovarian cancer cell migration and invasion

Microcarriers enhance brain cancer gene therapy efficacy

New potassium channel openers and uses thereof reported by Abbott team

Ariad designs new series of Src kinase SH2 antagonists

Nonemetogenic PDE4 inhibitors result from R&D at Inflazyme

New imidazoles jointly described by Novo Nordisk and Boehringer Ingelheim as H3 ligands

Benzimidazoles and benzotriazoles as chemokine receptor modulators

Aventis identifies cannabinoid CB1 receptor antagonists

Inhibitors of hormone-sensitive lipase (HSL) useful in diabetes and related disorders

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...